Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Concomitant HD, CAPD Effective for Chronic Renal Failure: Terumo Seminar
July 23, 2001
- Reports of Medical Device Malfunctions Increasing
July 23, 2001
- REGULATORY NEWS IN BRIEF
July 23, 2001
- Aventis Obtains World Rights to New Cancer Agent from Ajinomoto
July 23, 2001
- NBI's Sales Up 28% to 790 Million Euro in 2000: Prof. Krebs of Boehringer Ingelheim
July 23, 2001
- Int'l Standards of Efficacy, Safety Cross National Boundaries: Korosho Official
July 23, 2001
- Fujisawa Obtains Rights to New Immunosuppressants from Aventis
July 23, 2001
- JPMA to Propose New Drug Benefit System by End of Summer
July 16, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 16, 2001
- Sumitomo Licenses Hepatitis B Drug from Novirio
July 16, 2001
- OTC NEWS IN BRIEF
July 16, 2001
- Kasamatsu Meiki, Hokuho to Merge Within the Year
July 16, 2001
- MEDICAL DEVICE NEWS IN BRIEF
July 16, 2001
- BUSINESS NEWS IN BRIEF -1-
July 16, 2001
- Yonyaku: Sales Up Slightly to \55,276 Bil.
July 16, 2001
- BUSINESS NEWS IN BRIEF -2-
July 16, 2001
- National Medical Costs Up 3.7% to \30.9 Trillion
July 16, 2001
- BULLETIN
July 16, 2001
- 401 Generics Included in NHI Price List
July 16, 2001
- Alcos: Sales Down 2.7%, Operating Profit Down 70.3%
July 16, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…